Jeff Hatfield
Hatfield is CEO of Vividion Therapeutics, recently acquired by Bayer Pharmaceuticals. Previously, he was CEO of Vitae Pharmaceuticals andheld senior leadership positions at Bristol Myers Squibb. He currently serves on the Board of Vir Biotechnology and is an advisory board member of the Harvard Business School’s Biavatnik Fellowship in Life Science Entrepreneurship.
- October 2022
Added to: ROME Therapeutics - Cambridge, MA
ROME Therapeutics is a biotechnology company that is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome - vast stretches of uncharted genetic material that have long been dismissed as "junk DNA."